NewAmsterdam Pharma (NAMS) Operating Expenses (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Operating Expenses data on file, last reported at $61.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 14.52% year-over-year to $61.5 million; the trailing twelve-month figure through Mar 2026 stood at $237.7 million (changed 0.37% YoY), and the FY2025 full-year result was $248.2 million, up 11.87% from the prior year.
• Operating Expenses declined to $61.5 million in Q1 2026, from $66.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $71.9 million in Q1 2025 to a low of $44.2 million in Q2 2023.
• A 4-year average of $56.0 million and a median of $54.9 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses gained 26.41% in 2025 and slipped 14.52% in 2026, its largest moves.
• Tracing NAMS's Operating Expenses over 4 years: stood at $51.9 million in 2023, then climbed by 7.95% to $56.0 million in 2024, then climbed by 17.88% to $66.0 million in 2025, then decreased by 6.9% to $61.5 million in 2026.
• Business Quant data shows NAMS's Operating Expenses at $61.5 million in Q1 2026, $66.0 million in Q4 2025, and $55.5 million in Q3 2025.